Who is sponsoring NCT00072319?

NCT00072319 is sponsored by Memorial Sloan Kettering Cancer Center.

What condition does NCT00072319 study?

NCT00072319 studies Breast Cancer.

What drugs are being tested in NCT00072319?

Interventions: filgrastim, cyclophosphamide, epirubicin hydrochloride, paclitaxel, adjuvant therapy, neoadjuvant therapy.

What is the status of NCT00072319?

NCT00072319 is currently COMPLETED.

Last reviewed 2013-03-01 · How we verify

Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma

NCT00072319 Phase 2 COMPLETED

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery. Giving chemotherapy drugs after surgery may kill any remaining tumor cells. PURPOSE: Pilot trial to study the effectiveness of neoadjuvant or adjuvant epirubicin, cyclophosphamide, and paclitaxel in treating women who have stage I, stage II, or stage III breast cancer.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	COMPLETED
Start date	2003-08
Completion	2006-11

Conditions

Breast Cancer

Interventions

filgrastim
cyclophosphamide
epirubicin hydrochloride
paclitaxel
adjuvant therapy
neoadjuvant therapy

Countries

United States